We advised Novartis Finance S.A. on the issuance of EUR 600 million 3.100% fixed rate notes due 2032, EUR 600 million 3.500% fixed rate notes due 2035 and EUR 500 million 4.000% fixed rate notes due 2041.
The offering of the EUR 1.7 billion aggregate principal amount of notes was made through the group's Luxembourg subsidiary, Novartis Finance S.A., and guaranteed by Novartis AG.
Alongside Freshfields LLP (acting as English law advisers) and Homburger AG (acting as Swiss law advisers), our team advised on the Luxembourg capital markets aspects and assisted with the tax disclosure in connection with the transaction.